PE-22-28 Peptide Protocol & Dosing

What it is

PE-22-28 is a preclinical spadin-derived peptide that blocks TREK-1 potassium channels and shows antidepressant-like effects in animal models. Human trials are not available.

Evidence boundary

Preclinical / speculative. Do not present a human dosing schedule as established fact.

Trial evidence

No verified human trial found.

Preparation and measurement

Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
Phase	Dose	Draw / measure	Frequency	Weekly total
Weeks 1–2 (titration)	50 mcg	1 U (0.01 mL)	Daily during cycle	350 mcg/week
Weeks 3–8 (target)	100 mcg	2 U (0.02 mL)	Daily during cycle	700 mcg/week
Weeks 9–12 (optional)	150 mcg	3 U (0.03 mL)	Daily during cycle	1.05 mg/week
Weeks 13–16 (optional)	200 mcg	4 U (0.04 mL)	Daily during cycle	1.4 mg/week

Weeks 1–2 (titration)

Dose: 50 mcg
Draw / measure: 1 U (0.01 mL)
Frequency: Daily during cycle
Weekly total: 350 mcg/week

Weeks 3–8 (target)

Dose: 100 mcg
Draw / measure: 2 U (0.02 mL)
Frequency: Daily during cycle
Weekly total: 700 mcg/week

Weeks 9–12 (optional)

Dose: 150 mcg
Draw / measure: 3 U (0.03 mL)
Frequency: Daily during cycle
Weekly total: 1.05 mg/week

Weeks 13–16 (optional)

Dose: 200 mcg
Draw / measure: 4 U (0.04 mL)
Frequency: Daily during cycle
Weekly total: 1.4 mg/week

Weekly totals apply only during the active phase.

Titration rules

Daily titration (subcutaneous):
Weeks 1–2 (titration): 50 mcg/day.
Weeks 3–8 (target): 100 mcg/day. Common research dose.
Weeks 9–12 (optional): 150 mcg/day.
Weeks 13–16 (optional): 200 mcg/day. Upper end of researched range.
TREK-1 mechanism in the source literature
Limited human data

Practical rules

Pair with established mental-health care if relevant.
Do not present the dose ladder as validated human guidance.